abstract |
The present invention relates to the discovery that mutations in Nav1.7 are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the Nav1.7 gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for Nav1.7, and are useful in the treatment of pain and other Nav1.7-mediated disorders. The invention discloses potent and selective small molecule inhibitors of Nay1.7 and also relates to methods of using these compounds to treat or otherwise ameliorate such disorders. |